文献速递肝病

在社区中识别高危脂肪性肝病和肝纤维化

Detecting at-risk steatotic liver disease and liver fibrosis in the community.
PubMed 文献 · Hepatology · 2025-05-16

社区中伴有代谢危险因素和/或过量饮酒的脂肪性肝病患者中,约5%存在进展期肝纤维化、约10%存在高危代谢功能障碍相关脂肪性肝炎(At-Risk MASH)。推荐采用临床危险因素→FIB-4→弹性成像或直接肝纤维化生物标志物的序贯筛查路径,但灵敏度和特异度欠佳;社区实施肝纤维化筛查仍面临知识缺口、成本和检查可及性等障碍,需建立与专科衔接的路径。

要点

  • 社区脂肪性肝病患者中进展期肝纤维化约5%、高危MASH约10%。
  • 推荐序贯FIB-4与弹性成像或直接肝纤维化标志物筛查,但灵敏度和特异度欠佳。
  • 基层肝纤维化筛查面临知识缺口、成本、检查可及性和报告系统缺乏等障碍。

核心结论

  • 社区脂肪性肝病患者中进展期肝纤维化约5%、高危MASH约10%,识别这些患者对预后和管理至关重要。
  • 推荐对临床危险因素患者采用序贯FIB-4与弹性成像或直接肝纤维化生物标志物筛查,但灵敏度和特异度欠佳。
  • 基于血清和/或弹性成像的高危MASH生物标志物已在专科中心开发,但缺乏广泛验证,尤其在社区。
  • 基层研究证实肝纤维化筛查项目可增加未识别进展期肝病的检出,并可能减少不必要的专科转诊。
  • 部分数据显示对代谢功能障碍和酒精相关脂肪性肝病患者进行社区肝纤维化筛查具有成本效益。

研究设计与样本

  • 本文为综述,总结社区脂肪性肝病及肝纤维化筛查相关证据与推荐。

主要发现

  • 社区脂肪性肝病伴代谢危险因素和/或过量饮酒者中,进展期肝纤维化占5%、高危MASH占10%。
  • 序贯FIB-4与弹性成像或直接肝纤维化生物标志物的筛查路径被推荐,但灵敏度和特异度欠佳。
  • 高危MASH的血清和/或弹性成像生物标志物已在专科中心开发,但缺乏广泛验证,尤其在社区。
  • 基层肝纤维化筛查项目可增加未识别进展期肝病的检出,并可能减少不必要的专科转诊。
  • 部分数据显示代谢功能障碍和酒精相关脂肪性肝病患者社区肝纤维化筛查具有成本效益。

关键数值与推荐

  • 社区脂肪性肝病伴代谢危险因素和/或过量饮酒者中,进展期肝纤维化约5%、高危MASH约10%。
  • 推荐对临床危险因素患者采用序贯FIB-4与弹性成像或直接肝纤维化生物标志物筛查。

临床怎么用

  • 对社区脂肪性肝病伴代谢危险因素和/或过量饮酒者,推荐采用序贯FIB-4与弹性成像或直接肝纤维化生物标志物筛查进展期肝纤维化。
  • 识别高危MASH有助于筛选适合药物治疗的患者。
  • 识别进展期肝纤维化有助于指导预后和管理,因其肝失代偿和肝细胞癌风险增加。
  • 一旦识别目标患者,需建立与专科诊疗衔接的稳健路径。
  • 需在社区广泛实施系统性的循证诊断路径,以减少脂肪性肝病相关肝病负担。

局限性

  • 序贯FIB-4与弹性成像或直接肝纤维化生物标志物筛查路径的灵敏度和特异度欠佳。
  • 高危MASH的血清和/或弹性成像生物标志物已在专科中心开发,但缺乏广泛验证,尤其在社区。
  • 基层肝纤维化筛查面临知识缺口、成本、非侵入性检查可及性有限及缺乏整合的申请和报告系统等障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advanced liver fibrosis and "At-Risk" metabolic dysfunction-associated steatohepatitis (At-Risk MASH) are present in 5% and 10%, respectively, of community-based patients with steatotic liver disease and metabolic risk factors and/or excess alcohol consumption. Identification of these patients is critical to guide prognosis and management due to their increased risk of liver decompensation and HCC. In addition, identification of At-Risk MASH will assist in targeting those eligible for pharmacotherapy. Screening pathways for detecting advanced liver fibrosis, consisting of sequential Fibrosis-4 Index and elastography or direct liver fibrosis biomarkers in patients with clinical risk factors, are recommended; however have suboptimal sensitivity and specificity. Biomarkers based on serum and/or elastography for At-Risk MASH have been developed in specialist centres; however lack broad validation, particularly in the community. Currently a range of barriers have retarded adoption of liver fibrosis screening in primary care, including knowledge gaps regarding non-invasive testing, cost, and limited access of non-invasive tests, and lack of integrated ordering and reporting systems. Once target patients are identified, robust pathways for linkage to specialist care are needed. Despite these challenges, studies performed in primary care have confirmed that liver fibrosis screening programs increase the detection of unrecognized advanced liver disease and may reduce unnecessary specialist referrals. Furthermore, some data suggest that community-based screening of liver fibrosis in patients with metabolic dysfunction and alcohol-associated steatotic liver disease is cost-effective. Widespread implementation of systematic evidence-based diagnostic pathways in the community is needed to reduce liver-related morbidity related to steatotic liver disease.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Adams LA, Thiele M, Tsochatzis EA, et al. Detecting at-risk steatotic liver disease and liver fibrosis in the community. Hepatology. 2025. PMID: 40384127. doi:10.1097/HEP.0000000000001400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。